RVV — Revive Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$12.56m
- CA$12.00m
- 26
- 39
- 17
- 17
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.34 | 5.34 | 20.3 | 17.9 | 6.39 |
Operating Profit | -1.34 | -5.34 | -20.3 | -17.9 | -6.39 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.34 | -5.38 | -20.1 | -17.8 | -6.32 |
Net Income After Taxes | -1.34 | -5.38 | -20.1 | -17.8 | -6.32 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.34 | -5.38 | -20.1 | -17.8 | -6.32 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.34 | -5.38 | -20.1 | -17.8 | -6.32 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.021 | -0.05 | -0.069 | -0.056 | -0.016 |